These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38449476)

  • 1. Pregabalin Adjuventia Helped Risperidone-Induced Extrapyramidal Syndrome and Augmented Antipsychotic Response in an Adolescent with Schizophrenia.
    Naguy A; Pridmore S; Alamiri B
    Psychopharmacol Bull; 2024 Mar; 54(1):40-42. PubMed ID: 38449476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
    Mullen J; Jibson MD; Sweitzer D
    Clin Ther; 2001 Nov; 23(11):1839-54. PubMed ID: 11768836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
    Kopala LC; Good KP; Honer WG
    J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.
    Fleischhacker WW; Eerdekens M; Karcher K; Remington G; Llorca PM; Chrzanowski W; Martin S; Gefvert O
    J Clin Psychiatry; 2003 Oct; 64(10):1250-7. PubMed ID: 14658976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms.
    Lemmens P; Brecher M; Van Baelen B
    Acta Psychiatr Scand; 1999 Mar; 99(3):160-70. PubMed ID: 10100910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A syndrome of increased affect in response to risperidone among patients with schizophrenia.
    Ashleigh EA; Larsen PD
    Psychiatr Serv; 1998 Apr; 49(4):526-8. PubMed ID: 9550246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
    J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
    Caligiuri MP; Teulings HL; Dean CE; Niculescu AB; Lohr J
    Hum Mov Sci; 2009 Oct; 28(5):633-42. PubMed ID: 19692133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.
    Köhnke MD; Griese EU; Stösser D; Gaertner I; Barth G
    Pharmacopsychiatry; 2002 May; 35(3):116-8. PubMed ID: 12107857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel versus conventional antipsychotic drugs.
    Love RC
    Pharmacotherapy; 1996; 16(1 Pt 2):6-10. PubMed ID: 8778684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
    Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
    Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
    Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
    Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia.
    Azorin JM; Strub N; Loft H
    Int Clin Psychopharmacol; 2006 Jan; 21(1):49-56. PubMed ID: 16317317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
    Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.